Skip to main content

Table 5 6-month post-index all-cause healthcare utilization stratified by drug-drug interaction status

From: A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine

  Pregabalin Duloxetine
No DDI   No DDI  
DDI present present   DDI present present  
  n = 433 n = 13 Pvalue* n = 193 n = 253 Pvalue*
All-Cause Inpatient Visits       
Members with Hospitalization 123 (28.4%) 1 (7.7%) ** 49 (25.4%) 90 (35.6%) 0.0214
Hospitalizations Per Member, Mean (SD) 0.9 (2.8) 0.1 (0.3) 0.0897 0.5 (1.9) 1.3 (3.9) 0.0059
All-Cause Emergency Room Visits       
Members with Visit 100 (23.1%) 3 (23.1%) ** 40 (20.7%) 83 (32.8%) 0.0047
Visits per Member, Mean (SD) 0.5 (1.2) 0.6 (1.2) 0.8068 0.4 (1.0) 0.7 (1.2) 0.0035
All-Cause Outpatient Visits (non-physical therapy)       
Members with Visit 427 (98.6%) 13 (100.0%) ** 190 (98.4%) 250 (98.8%) **
Visits per Member, Mean (SD) 14.6 (12.6) 12.8 (9.1) 0.7728 15.2 (13.6) 17.3 (11.1) 0.0044
All-Cause Physical Therapy Visits       
Members with Visit 57 (13.2%) 2 (15.4%) ** 33 (17.1%) 32 (12.6%) 0.1869
Visits per Member, Mean (SD) 0.8 (3.1) 0.3 (0.9) 0.8733 1.0 (4.1) 0.9 (3.5) 0.2342
  1. *All P values for categorical variables calculated using Chi Square tests. All P values for continuous variables calculated using Wilcoxon Rank-Sum tests.
  2. **Expected Counts <5. Chi-square test may not be appropriate.
  3. DDI, Drug-Drug Interaction.
  4. SD, Standard Deviation.